Shuangcheng Pharmaceutical is a leading peptide pharmaceutical company in China. Its main product is the new injectable thymus method, which has the 3rd largest domestic market share. It is expected that the company's injectable thymus method will maintain steady growth in the last 3 years. The EPS for 12-14 is expected to be 0.71, 0.89, and 1.03 yuan respectively. Based on an estimate of 25 to 30 times PE in 2012, the company's reasonable inquiry range is: 17.04 to 19.88 yuan.
【招商证券】双成药业IPO投资价值分析报告:多肽仿制药制剂领先者
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.